post-cal view earn upsid enough drive
share higher today particularli ralli ytd vs
jan posit pre-announce see note
pre-announce elat encourag strengthen core life
scienc diagnost segment robust order demand
continu opportun biopharma well contribut faster-
grow acquisit cepheid phenomenex hsd
continu propel core organ growth rate
despit monument chang forecast rais
target price heighten convict above-consensu
ep estim reflect continu momentum core
revenu growth accompani profit margin leverag details/thought
segment perform enclos
reiter outperform ebitda share trade
peer fulli reflect lt growth prospect strong
accompani cash flow importantli continu view step
activ immin key compon growth strategi hold
ampl dri power reload balanc sheet rel quiet
risk call includ slowdown fundament util trend
unfavor regulatori reimburs shift acquisit miscu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
lead manufactur system instrument
consum broad array purpos custom
diagnost dental environment health/appli scienc
price jan rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
acceler key end market global signific rebound
dental trend better expect implement db
acquir compani market share gain materi margin
grey sky scenario base signific weak
key end market prolong weak dental demand trend
deceler core growth acquisit integr headwind
in-lin pre-announce previou manag commentari core organ
revenu growth acceler meaning level nearli subseg
exclud dental cap year strongest growth trend head
maintain construct thesi build convict diversifi
margin improv capit deploy opportun could offer upsid
recap organ revenu plan strength life scienc
vs estimate diagnost vs estimate environ appli
solut vs estimate off-set unsurpris continu weak dental
vs estimate flat gross margin improv bp bp plan larg
driven cepheid pall sg increas bp bp higher plan
ebitda margin improv bp yoy though bp plan free cash
flow million cash reserv stand million total debt
life scienc revenu
life scienc post impress organ growth vs estimate includ
approxim bp pull order due inclement weather
exclud benefit core growth rose still repres impress acceler
core oper profit margin also improv nice bp
bec life scienc grew hsd driven demand flow cytometri particl
pall revenu improv partial help fulfil order neg
impact inclement weather hurrican underli bright spot quarter
includ demand microelectron single-us technolog importantli
manag highlight strong order growth trend larg continu
januari dynam provid greater visibl continu strength
leica microsystem lsd moder slightli msd particular
strength western european chines medic research end market
sciex msd in-lin experi demand food environment
pharmaceut end market
dental revenu
dental revenu fell heel rise trend rel
unsurpris given well-docu continu weak tradit consum
on-going disrupt equip distribut relationship core revenu larg
driven strength specialti consum implant orthodont grow msd
compris hsd growth nobel impli lsd growth ormco anem
tradit consum well weak equip sale neg impact
dentspli sirona distributor partnership realign off-set
aforement bright spot specialti disclosur includ msd growth
specialti consum msd declin equip sale l-msd declin tradit
tradit consum growth clearli
disappoint past sever quarter manag highlight believ
destock trend stabil posit progress note
compani also note
broader
manufacturer/distributor partnership realign xray/henri schein/patterson
weigh equip sale balanc headwind
expect headwind
charl martineau pm univers toronto mitig continu strength specialti consum well subsid
destock headwind tradit consum make inher easier annual
comp
figur quarterli equip consum util metric
note disclos dental consum equip organ growth rate
diagnost revenu
diagnost slightli aggress estim
perform driven predominantli inclus cepheid core sale
sequenti acceler beckman diagnost segment core oper margin
improv healthi bp detail underli dynam across product line
cepheid acquir novemb sale rose broad-bas
strength across major geographi product line strong perform
contribut roughli growth full year doubl initi
manag expect term integr dilig implement db
initi help sustain oper margin expans overal integr seemingli
remain track evidenc bp gross margin expans sinc
beckman coulter diagnost lsd driven growth china latin
america notabl area strength includ continu strong demand
immunoassay urinalysi clinic chemistri product line
radiomet msd deceler hsd partial attribut tough yoy
compar growth blood ga aqt product consist previou
leica biosystem hsd acceler msd growth strength north
america western europ perform led advanc stain
histolog consist previou quarter
environment appli solut revenu
revenu increas organ basi expect
solid perform across busi line also help recoveri trojan dd
equipment/consum consist previou quarter demand packag
color solut driven north america western europ
videojet hsd driven major product categori across
msd driven market
qualiti core revenu increas msd sequenti improv lsd
growth
hach msd solid growth municip industri end market
europ china note hach complet two acquisit quarter
includ applitek manufactur supplier wet chemic biolog
on-line analyz kipp zonen manufactur distributor instrument
measur solar radiat atmospher properti
trojan post doubl digit growth strong bid activ north america
municip market also reflect favor custom win rate market
chemtreat lsd help strength food steel oil ga end market
particularli north america
forecast revenu grow core growth billion driven
sustain momentum life scienc diagnost
slight growth dental estim adjust oper margin
expans bp owe larg pall margin ramp within life scienc
segment well dbs-driven effici initi across cepheid on-going
oper effici initi dental overal ep rise also
help lower interest expens slightli better tax rate
forecast revenu rise billion driven rel consist
core growth across segment life scienc diagnost
 estim step dental oper margin
expand bp continu dbs-deriv effici initi ep
increas
ebitda share trade peer fulli reflect
lt growth prospect strong accompani cash flow target price
base ev/ebitda multipl in-lin peer view
warrant greater convict revenu earn growth prospect
research develop
research develop
research develop
growth acquisit
growth fx
total fx impact revenu
compani mention price
